Familial Alzheimer's Disease-associated Presenilin-1 Alters Cerebellar Activity and Calcium Homeostasis
Overview
Authors
Affiliations
Familial Alzheimer's disease (FAD) is characterized by autosomal dominant heritability and early disease onset. Mutations in the gene encoding presenilin-1 (PS1) are found in approximately 80% of cases of FAD, with some of these patients presenting cerebellar damage with amyloid plaques and ataxia with unclear pathophysiology. A Colombian kindred carrying the PS1-E280A mutation is the largest known cohort of PS1-FAD patients. Here, we investigated PS1-E280A-associated cerebellar dysfunction and found that it occurs early in PS1-E208A carriers, while cerebellar signs are highly prevalent in patients with dementia. Postmortem analysis of cerebella of PS1-E280A carrier revealed greater Purkinje cell (PC) loss and more abnormal mitochondria compared with controls. In PS1-E280A tissue, ER/mitochondria tethering was impaired, Ca2+ channels IP3Rs and CACNA1A were downregulated, and Ca2+-dependent mitochondrial transport proteins MIRO1 and KIF5C were reduced. Accordingly, expression of PS1-E280A in a neuronal cell line altered ER/mitochondria tethering and transport compared with that in cells expressing wild-type PS1. In a murine model of PS1-FAD, animals exhibited mild ataxia and reduced PC simple spike activity prior to cerebellar β-amyloid deposition. Our data suggest that impaired calcium homeostasis and mitochondrial dysfunction in PS1-FAD PCs reduces their activity and contributes to motor coordination deficits prior to Aβ aggregation and dementia. We propose that PS1-E280A affects both Ca2+ homeostasis and Aβ precursor processing, leading to FAD and neurodegeneration.
Inflammasomes in Alzheimer's Progression: Nrf2 as a Preventive Target.
Lopez-Hernandez R, de la Torre-Alamo M, Garcia-Bueno B, Baroja-Mazo A, Fenoy F, Cuevas S Antioxidants (Basel). 2025; 14(2).
PMID: 40002308 PMC: 11851705. DOI: 10.3390/antiox14020121.
Cerebellum in neurodegenerative diseases: Advances, challenges, and prospects.
Liu G, Yang C, Wang X, Chen X, Cai H, Le W iScience. 2024; 27(11):111194.
PMID: 39555407 PMC: 11567929. DOI: 10.1016/j.isci.2024.111194.
Dysregulated mTOR networks in experimental sporadic Alzheimer's disease.
de la Monte S, Tong M Front Cell Neurosci. 2024; 18:1432359.
PMID: 39386180 PMC: 11461251. DOI: 10.3389/fncel.2024.1432359.
Monoclonal antibodies and aptamers: The future therapeutics for Alzheimer's disease.
Barrera-Ocampo A Acta Pharm Sin B. 2024; 14(7):2795-2814.
PMID: 39027235 PMC: 11252463. DOI: 10.1016/j.apsb.2024.03.034.
Yang C, Liu G, Chen X, Le W MedComm (2020). 2024; 5(7):e638.
PMID: 39006764 PMC: 11245631. DOI: 10.1002/mco2.638.